Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, is investigating potential claims on behalf of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) stockholders. The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. This decision was based on a prespecified interim analysis indicating a low probability of demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to assist the investigation by visiting bgandg.com/SYRS. The law firm represents investors in securities fraud class actions and shareholder derivative suits on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Bronstein, Gewirtz & Grossman sta indagando su potenziali rivendicazioni per conto degli azionisti di Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L'indagine è stata avviata dopo l'annuncio di Syros del 12 agosto 2024, riguardante la cessazione delle iscrizioni nello studio clinico di fase 2 SELECT-AML-1 per il trattamento della leucemia mieloide acuta (AML). Questa decisione è stata presa sulla base di un'analisi intermedia predefinita che indicava una bassa probabilità di dimostrare superiorità nell'analisi finale.
Gli investitori che hanno acquistato titoli Syros sono incoraggiati a contribuire all'indagine visitando bgandg.com/SYRS. Lo studio legale rappresenta investitori in azioni collettive per frode sui titoli e azioni derivatif per gli azionisti su base di compenso successoria, cercando il rimborso delle spese e delle spese legali solo se avranno successo.
Bronstein, Gewirtz & Grossman está investigando posibles reclamaciones en nombre de los accionistas de Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). La investigación se inició tras el anuncio de Syros el 12 de agosto de 2024, que declaró que interrumpirá la inscripción en el ensayo clínico de fase 2 SELECT-AML-1 para el tratamiento de la leucemia mieloide aguda (AML). Esta decisión se basó en un análisis interino predefinido que indicaba una baja probabilidad de demostrar superioridad en el análisis final.
Se anima a los inversionistas que compraron valores de Syros a ayudar con la investigación visitando bgandg.com/SYRS. El bufete de abogados representa a inversionistas en acciones colectivas sobre fraude en valores y acciones derivadas de accionistas sobre una base de honorarios de contingencia, buscando el reembolso de los gastos y honorarios de abogados solo si tiene éxito.
Bronstein, Gewirtz & Grossman은 Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) 주주를 대신하여 잠재적 청구 사항을 조사하고 있습니다. 이 조사는 Syros가 2024년 8월 12일에 급성 골수성 백혈병(AML) 치료를 위한 SELECT-AML-1 2상 임상 시험의 등록을 중단할 것이라고 발표한 것에 따라 진행됩니다. 이 결정은 최종 분석에서 우수성을 입증할 가능성이 낮다는 미리 정해진 중간 분석에 근거했습니다.
Syros 증권을 구매한 투자자들은 bgandg.com/SYRS를 방문하여 조사에 도움을 줄 것을 권장합니다. 이 법률 사무소는 유가증권 사기 집단 소송 및 주주 파생 소송에서 투자자를 대리하며, 성공할 경우에만 비용 및 변호사 수임료를 환급받도록 하는 성과 보수 기반으로 운영됩니다.
Bronstein, Gewirtz & Grossman enquête sur d'éventuelles réclamations au nom des actionnaires de Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L'enquête fait suite à l'annonce de Syros le 12 août 2024, selon laquelle elle cessera l'inscription à l'essai clinique de phase 2 SELECT-AML-1 pour le traitement de la leucémie myéloïde aiguë (LMA). Cette décision était fondée sur une analyse intérimaire prédéfinie indiquant une faible probabilité de démontrer une supériorité lors de l'analyse finale.
Les investisseurs ayant acheté des titres Syros sont encouragés à aider l'enquête en visitant bgandg.com/SYRS. Le cabinet d'avocats représente des investisseurs dans des actions collectives pour fraude sur les valeurs mobilières et des actions dérivées des actionnaires sur une base d'honoraires de résultat, recherchant un remboursement des frais et des honoraires d'avocat uniquement en cas de succès.
Bronstein, Gewirtz & Grossman untersucht potenzielle Ansprüche im Namen von Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Aktionären. Die Untersuchung folgt auf die Ankündigung von Syros am 12. August 2024, dass die Teilnehmerregistrierung in der SELECT-AML-1 Phase 2 klinischen Studie zur Behandlung von akuter myeloischer Leukämie (AML) eingestellt wird. Diese Entscheidung basierte auf einer vordefinierten Zwischenanalyse, die eine geringe Wahrscheinlichkeit zeigte, bei der abschließenden Analyse Überlegenheit zu demonstrieren.
Investoren, die Syros-Wertpapiere gekauft haben, werden ermutigt, die Untersuchung zu unterstützen, indem sie bgandg.com/SYRS besuchen. Die Kanzlei vertritt Investoren in Sammelklagen wegen Wertpapierbetrugs und Aktionärsderivatklagen auf Erfolgsbasis und strebt eine Erstattung von Ausgaben und Anwaltsgebühren nur im Erfolgsfall an.
- None.
- Discontinuation of enrollment in SELECT-AML-1 Phase 2 clinical trial
- Low probability of demonstrating treatment superiority in AML therapy
- Potential legal claims against the company
- Possible negative impact on investor confidence and stock value
The discontinuation of enrollment in Syros Pharmaceuticals' SELECT-AML-1 Phase 2 clinical trial is a significant setback for the company's AML treatment program. This decision, based on a low probability of success in demonstrating superiority, could have substantial implications for Syros' pipeline and future revenue prospects.
The trial's focus on tamibarotene in combination with established AML treatments venetoclax and azacitidine represented a potential differentiation strategy for Syros in the competitive AML market. The failure to show superiority may limit the company's market positioning and could lead to a reevaluation of its R&D strategy.
Investors should closely monitor Syros' next steps, including potential pipeline reprioritization and any impact on the company's cash runway. This news may also affect investor confidence in Syros' other ongoing clinical programs and its ability to bring novel therapies to market.
The investigation by Bronstein, Gewirtz & Grossman, into Syros Pharmaceuticals raises potential legal and regulatory concerns. Such investigations often focus on whether the company adequately disclosed material information to investors in a timely manner.
Key points of interest include the timing of the trial's discontinuation announcement and whether Syros had prior knowledge that could have been communicated to shareholders earlier. The law firm's involvement suggests a possible class action lawsuit, which could lead to financial liabilities and reputational damage for Syros.
Investors should be aware that these investigations can be lengthy processes and may not always result in legal action. However, the mere existence of such an investigation can create uncertainty and volatility in the stock price. Shareholders should stay informed about any developments and consider the potential impact on their investment decisions.
NEW YORK CITY, NY / ACCESSWIRE / August 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Investigation Details
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
What's Next?
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View the original press release on accesswire.com
FAQ
What is the reason for the investigation into Syros Pharmaceuticals (SYRS)?
What clinical trial did Syros Pharmaceuticals (SYRS) discontinue on August 12, 2024?
How can Syros Pharmaceuticals (SYRS) investors participate in the investigation?
What are the potential consequences for Syros Pharmaceuticals (SYRS) following the discontinuation of the clinical trial?
